Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A

Vincent P. Diego, Bernadette W. Luu, Marco Hofmann, Long V. Dinh, Marcio Almeida, Jerry S. Powell, Raja Rajalingam, Juan M. Peralta, Satish Kumar, Joanne E. Curran, Zuben E. Sauna, Roberta Kellerman, Yara Park, Nigel S. Key, Miguel A. Escobar, Huy Huynh, Anne M. Verhagen, Sarah Williams-Blangero, Paul V. Lehmann, Eugene MaraskovskyJohn Blangero, Tom E. Howard

Research output: Contribution to journalArticle

Abstract

Background: Plasma-derived (pd) or recombinant (r) therapeutic factor VIII proteins (FVIIIs) are infused to arrest/prevent bleeding in patients with hemophilia A (PWHA). However, FVIIIs are neutralized if anti-FVIII-antibodies (inhibitors) develop. Accumulating evidence suggests that pdFVIIIs with von Willebrand factor (VWF) are less immunogenic than rFVIIIs and that distinct rFVIIIs are differentially immunogenic. Since inhibitor development is T-helper-cell-dependent, human leukocyte antigen (HLA)-class-II (HLAcII) molecules constitute an important early determinant. Objectives: Use dendritic cell (DC)-protein processing/presentation assays with mass-spectrometric and peptide-proteomic analyses to quantify the DP-bound, DQ-bound, and DR-bound FVIII-derived peptides in individual HLAcII repertoires and compare the immunogenic potential of six distinct FVIIIs based on their measured peptide counts. Patients/Methods: Monocyte-derived DCs from normal donors and/or PWHA were cultured with either: Mix-rFVIII, a VWF-free equimolar mixture of a full-length (FL)-rFVIII [Advate® (Takeda)] and four distinct B-domain-deleted (BDD)-rFVIIIs [Xyntha® (Pfizer), NovoEight® (Novo-Nordisk), Nuwiq® (Octapharma), and Afstyla® (CSL Behring GmBH)]; a pdFVIII + pdVWF [Beriate® (CSL Behring GmBH)]; Advate ± pdVWF; Afstyla ± pdVWF; and Xyntha + pdVWF. Results: We showed that (i) Beriate had a significantly lower immunogenic potential than Advate ± pdVWF, Afstyla − pdVWF, and Mix-rFVIII; (ii) distinct FVIIIs differed significantly in their immunogenic potential in that, in addition to (i), Afstyla + pdVWF had a significantly lower immunogenic potential than Beriate, while the immunogenic potential of Beriate was not significantly different from that of Xyntha + pdVWF; and (iii) rFVIIIs with pdVWF had significantly lower immunogenic potentials than the same rFVIIIs without pdVWF. Conclusions: Our results provide HLAcII peptidomic level explanations for several important clinical observations/issues including the differential immunogenicity of distinct FVIIIs and the role of HLAcII genetics in inhibitor development.

Original languageEnglish (US)
Pages (from-to)201-216
Number of pages16
JournalJournal of Thrombosis and Haemostasis
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2020
Externally publishedYes

Keywords

  • blood coagulation factor inhibitors
  • factor VIII
  • hemophilia A
  • histocompatibility antigens class II
  • peptide
  • quantitative peptidomics
  • sequence analysis

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A'. Together they form a unique fingerprint.

  • Cite this

    Diego, V. P., Luu, B. W., Hofmann, M., Dinh, L. V., Almeida, M., Powell, J. S., Rajalingam, R., Peralta, J. M., Kumar, S., Curran, J. E., Sauna, Z. E., Kellerman, R., Park, Y., Key, N. S., Escobar, M. A., Huynh, H., Verhagen, A. M., Williams-Blangero, S., Lehmann, P. V., ... Howard, T. E. (2020). Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. Journal of Thrombosis and Haemostasis, 18(1), 201-216. https://doi.org/10.1111/jth.14647